CDK2
45 programs · 43 companies
Programs
45
Companies
43
Active Trials
26
Targeting CDK2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | TTR AmyloidosisDravet | |
| NVS-3297 | Novartis | Preclinical | CLLWM | |
| Fixainavolisib | Takeda | Preclinical | Ovarian CaNASH | |
| AMG-1919 | Amgen | Phase 2/3 | EpilepsyGBM | |
| AMG-415 | Amgen | Phase 1 | ETAsthma | |
| AMG-9052 | Amgen | Phase 2/3 | MigraineMM | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | BCCParkinson's | |
| Nirabrutinib | BioNTech | Phase 2/3 | CF | |
| BII-8315 | Biogen | NDA/BLA | Prostate CaALL | |
| ALN-3284 | Alnylam | Phase 2/3 | PTSDPV | |
| Tixatapinarof | Arvinas | Phase 1/2 | CSU | |
| Gelitapinarof | MacroGenics | Approved | PNH | |
| Voxafotisoran | CSL Limited | Phase 1 | RBWilms | |
| KAR-3569 | Karuna (BMS) | NDA/BLA | MMAML | |
| RIN-657 | Ring Ther | Phase 1 | CML | |
| Elratenlimab | EQRx | Phase 3 | PNHPAH | |
| ZNT-6525 | Zentalis | Phase 1 | Pancreatic CaPompe | |
| IMV-6752 | Imvax | Phase 2 | FLCholangiocarcinoma | |
| Zorilemzoparlimab | Morphic Ther (Lilly) | Approved | AMLBladder Ca | |
| Niraderotide | Vera Therapeutics | Phase 2/3 | Parkinson'sMG | |
| Rilucapivasertib | Lantern Pharma | Phase 2/3 | GA | |
| MEI-6717 | MEI Pharma | Phase 2 | MyelofibrosisFSGS | |
| ELO-7470 | Eloxx Pharma | Preclinical | MS | |
| ANR-8751 | Alto Neuroscience | Phase 2/3 | MDDWilms | |
| DRR-2203 | Durect (Innocoll) | Phase 2/3 | HCCSLE | |
| Zorirelsin | Celltrion | Phase 3 | PsoriasisSLE | |
| Gelituximab | Affinia | NDA/BLA | RSV | |
| HAR-6503 | Harmony Bio | Approved | MigraineCKD | |
| IVE-3532 | Iveric (Astellas) | Phase 1 | Hemophilia ARCC | |
| Tirazanubrutinib | Phathom Pharma | Preclinical | SCLC | |
| Tiralucimab | Intercept (Alfasigma) | NDA/BLA | MDS | |
| 459-2528 | Healios | Preclinical | PNH | |
| Gozesertib | Trillium (Pfizer) | Phase 1/2 | GAMeso | |
| BER-6094 | BerGenBio | Phase 3 | OCDNB | |
| Kemavorutinib | Plurilock | Phase 2/3 | PVBreast Ca | |
| Gelizasiran | Organon | Phase 2/3 | ThymomaFSGS | |
| Gozesertib | Mithra Pharma | Phase 1/2 | PompeADPKD | |
| LIO-530 | Liomont | Phase 1 | PNH | |
| RUI-IIT-701 | Ruijin Hospital | Phase 1 | SMA | |
| RAB-IIT-788 | Rabin Medical Center | NDA/BLA | Wilms | |
| Fixatuximab | Bio-Techne | Approved | Prostate CaALL | |
| A-568 | Agilent Technologies | Approved | RB | |
| STA-2404 | Stada Arzneimittel | NDA/BLA | Huntington's | |
| Sovazanubrutinib | SK Biopharm | Phase 2/3 | SMANB | |
| PAT-6991 | PathAI | Phase 1/2 | RAMCL |